Xiamen Bluebay Science & Technology

Xiamen Bluebay Science & Technology is a Chinese marine biotechnology and biopharmaceutical company founded in 2005. The company specializes in the research, development, production, and commercialization of high-purity marine biomaterials, dietary supplements, and pharmaceuticals, most notably high-purity glucosamine sulfate (purity >99%) and chitooligosaccharides. In 2024, Bluebay successfully obtained drug registration and manufacturing approvals for its glucosamine sulfate drug product, establishing itself as a key player in the treatment of osteoarthritis and joint health. Headquartered in Xiamen's Bio-industry Park, the company operates a large-scale manufacturing facility and collaborates with prominent academic institutions to advance marine-derived therapeutics.